Scaling Spray Drying for Tomorrow’s Therapies to Ensure Supply Chain Resilience

Pharmaceutical development is increasingly shaped by two converging challenges: the technical complexity of formulating emerging molecules and the external pressures of volatile global supply chains. Bioavailability constraints and stability continue to limit progress for small molecules and peptides, while tariffs, geopolitical risks, and onshoring initiatives are redefining cost structures and manufacturing localization strategies. Spray drying has evolved to be the leading technology for bioavailability enhancement of oral dosage forms through the manufacturing of amorphous solid dispersions. It is also the preferred technology for inhalation particle engineering for high drug loads and remains a versatile platform to isolate, increase stability, and improve delivery performance across several pharmaceutical modalities and functional ingredients. By scaling up efficiently to commercial volumes, large capacity spray dryers enable sponsors to advance programs more quickly and accelerate commercial readiness while strengthening supply resilience. When large-scale capacity is considered early in development, it reduces the risk of reformulation, accelerates timelines, and lowers cost of goods for high-volume therapies. This session will highlight how spray drying supports technical success and portfolio resilience, providing a strategic lens on technology adoption in a changing global market.